Travere Therapeutics today announced that the Company will present seven abstracts at the upcoming ERA Congress in Vienna, Austria, in June.

As the years and months pass by, my health, due to my kidney failure, has further deteriorated. I fear that I will not ...

Opening of Japan’s first clinical trial site for ACTION3 triggers the first development milestone payment of ¥400 million ...

AI is reshaping labs and Clever Culture’s tech is gaining Big Pharma attention as diagnostics and cleanrooms go digital.

Earlier this year, Filspari also failed to meet its objectives in a pivotal trial in focal segmental glomerulosclerosis (FSGS), another rare kidney disease, in which the comparator drug was also ...

as well as TRPC6 inhibitor BI 764198 in phase 2 for rare kidney disease focal segmental glomerulosclerosis (FSGS). In oncology, she highlighted MDM2-p53 antagonist brigimadlin, which has advanced ...

ND0612 is an investigational drug-device therapy that provides a 24-hour continuous subcutaneous infusion of levodopa/carbidopa solution. The Food and Drug Administration (FDA) has accepted for ...

Dimerix has opened the first trial site in Japan for its ACTION3 phase III drug candidate DMX-200 to treat focal segmental glomerulosclerosis (FSGS) kidney disease. Opening of Japan’s first ...

In this episode, host Tylah Tully unpacks Titanium Sands (ASX:TSL) latest news after they were awarded one year retention licences for the company's Sri Lankan heavy mineral sands project ...

Bailador Technology Investments is reaping the early rewards of its investment in fintech platform DASH Technology Group, which has reported strong H2 FY25 growth. For H2 FY25 DASH has reported ...